Amplia advances pancreatic cancer trial planning as quarterly cash falls to $21 million
ATX: $0.083 +5.06% · MC: $45M
Amplia said its ACCENT pancreatic cancer trial is nearing completion and it is planning a registrational study, with Australian sites preparing to start the initial stage and a US FDA design meeting planned for the second quarter of 2027. September-quarter operating cash outflows eased to about $3 million from about $4 million in the previous quarter, while cash declined to about $21 million from about $24 million at June-end; a research tax refund received in October lifted the pro forma balance to about $26 million. The company also highlighted its Eli Lilly collaboration to study narmafotinib with an experimental lung cancer drug.

Comments